Loading...
XASE
NBY
Market cap4mUSD
Jul 11, Last price  
0.69USD
1D
6.51%
1Q
30.59%
Jan 2017
-99.98%
IPO
-100.00%
Name

NovaBay Pharmaceuticals Inc

Chart & Performance

D1W1MN
P/E
—
P/S
0.41
EPS
—
Div Yield, %
—
Shrs. gr., 5y
40.59%
Rev. gr., 5y
8.11%
Revenues
10m
-33.81%
01,533,0005,913,0006,722,00015,684,0009,754,00011,019,0006,947,0003,477,0001,054,0004,381,00011,897,00018,230,00012,508,0006,599,0009,934,0008,421,00014,404,00014,726,0009,747,000
Net income
-9m
L-10.71%
-3,463,000-5,286,000-5,400,000-8,114,0002,697,000-4,308,000-5,085,000-7,027,000-16,042,000-15,194,000-18,973,000-13,151,000-7,403,000-6,545,000-10,487,000-11,039,000-6,559,000-16,265,000-9,640,000-8,608,000
CFO
-5m
L+25.47%
-3,230,0004,744,000-6,271,000-9,942,000-1,648,0002,028,000-3,142,000-6,528,000-12,969,000-15,055,000-18,559,000-12,135,000-6,270,000-5,568,000-7,929,000-4,721,000-9,192,000-6,654,000-4,131,000-5,183,000
Earnings
Aug 11, 2025

Profile

NovaBay Pharmaceuticals, Inc., a pharmaceutical company, develops and sells eyecare and skincare products in the United States and internationally. It offers Avenova, a solution for removing foreign materials, including microorganisms and debris from skin around the eye, such as the eyelid; and wound care products under the NeutroPhase and PhaseOne brands. The company also provides dermatological solutions to address skincare concerns comprising keratosis pilaris, rosacea and eczema, anti-aging, SPF, hyperhidrosis, excessive hair, and acne under the DERMAdoctor brand. It sells its products through retailers, digital beauty channels, and distributors, as well as online. The company was formerly known as NovaCal Pharmaceuticals, Inc. and changed its name to NovaBay Pharmaceuticals, Inc. in February 2007. NovaBay Pharmaceuticals, Inc. was incorporated in 2000 and is headquartered in Emeryville, California.
URL
https://novabay.com/
IPO date
Oct 26, 2007
Employees
29
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
9,747
-33.81%
14,726
2.24%
14,404
71.05%
Cost of revenue
14,721
19,729
22,084
Unusual Expense (Income)
NOPBT
(4,974)
(5,003)
(7,680)
NOPBT Margin
Operating Taxes
(3,809)
Tax Rate
NOPAT
(4,974)
(5,003)
(3,871)
Net income
(8,608)
-10.71%
(9,640)
-40.73%
(16,265)
147.98%
Dividends
Dividend yield
Proceeds from repurchase of equity
2,858
3,565
4,738
BB yield
Debt
Debt current
463
2,127
453
Long-term debt
1,816
2,711
3,629
Deferred revenue
Other long-term liabilities
334
Net debt
1,849
1,708
(1,764)
Cash flow
Cash from operating activities
(5,183)
(4,131)
(6,654)
CAPEX
(6)
(19)
(112)
Cash from investing activities
1,064
(19)
(112)
Cash from financing activities
1,500
1,910
4,633
FCF
(2,281)
(4,590)
(5,041)
Balance
Cash
430
3,130
5,362
Long term investments
484
Excess cash
2,394
5,126
Stockholders' equity
(183,402)
(172,787)
(154,527)
Invested Capital
184,445
179,670
167,122
ROIC
ROCE
EV
Common stock shares outstanding
3,396
120
1,610
Price
Market cap
EV
EBITDA
(4,934)
(4,800)
(7,197)
EV/EBITDA
Interest
904
3,809
Interest/NOPBT